Brain natriuretic peptide is a prognostic parameter in chronic lung disease. (Q48686597)

14 February 2018

title

Brain natriuretic peptide is a prognostic parameter in chronic lung disease. (English)

1 reference

14 February 2018

author name string

Hanno H Leuchte

1

1 reference

14 February 2018

Rainer A Baumgartner

2

1 reference

14 February 2018

Michal El Nounou

3

1 reference

14 February 2018

Michael Vogeser

4

1 reference

14 February 2018

Claus Neurohr

5

1 reference

14 February 2018

Michael Trautnitz

6

1 reference

14 February 2018

Juergen Behr

7

1 reference

14 February 2018

language of work or name

English

0 references

publication date

13 January 2006

1 reference

14 February 2018

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

14 February 2018

volume

173

1 reference

14 February 2018

issue

7

1 reference

14 February 2018

page(s)

744-750

1 reference

14 February 2018

Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Predicting mortality in patients with sarcoidosis awaiting lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

21 January 2018

Chronic cor pulmonale

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Clinical classification of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: response to iloprost inhalation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Clinical significance of brain natriuretic peptide in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

21 January 2018

Statement on Sarcoidosis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Plasma natriuretic peptide levels and the risk of cardiovascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Pulmonary arterial hypertension: the key role of echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

Severe pulmonary hypertension and chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200510-1545OC

10.1164/RCCM.200510-1545OC

21 January 2018

Identifiers

DOI

1 reference

14 February 2018

PubMed ID

16415273

1 reference

14 February 2018